Rheumatoid Arthritis News and Research RSS Feed - Rheumatoid Arthritis News and Research

Rheumatoid arthritis (RA) is a chronic disease of the joints that can cause a disabling degree of pain and significantly interfere with an individual’s day-to-day living.

RA is an autoimmune disease, meaning the immune system, which is usually geared up to fight infection, attacks the lining of the joints, causing them to swell and become stiff and painful. Eventually, the joint itself can become damaged as well as the cartilage and surrounding bone. Any joint can be affected but most commonly the illness involves the hands, feet and wrists.

The condition is more common among women than men and usually affects people between the ages of 40 and 70, although it can affect people of any age.

Symptoms range from mild to severe and can flare-up suddenly and unpredictably, making the condition very difficult to live with.

The exact cause of rheumatoid arthritis is not yet fully understood but some research suggests that viruses and bacteria may be involved. RA cannot be cured but early diagnosis and treatment can help to manage symptoms and prevent disability.
Study identifies new signaling pathway that leads to inflammatory bone erosion in RA patients

Study identifies new signaling pathway that leads to inflammatory bone erosion in RA patients

A new study by researchers at Hospital for Special Surgery identifies a new signaling pathway that contributes to the development and progression of inflammatory bone erosion, which occurs in patients with rheumatoid arthritis (RA). Rheumatoid arthritis is a systemic inflammatory autoimmune disease that affects millions of adults worldwide. [More]
Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications. [More]
BIDMC scientists uncover new class of molecules that protects against diabetes

BIDMC scientists uncover new class of molecules that protects against diabetes

Scientists at the Salk Institute and Beth Israel Deaconess Medical Center in Boston have discovered a new class of molecules—produced in human and mouse fat—that protects against diabetes. [More]
TSRI, STSI researchers receive NIH grants to set up platforms to mine biomedical data

TSRI, STSI researchers receive NIH grants to set up platforms to mine biomedical data

San Diego researchers at The Scripps Research Institute and Scripps Translational Science Institute will receive more than $4.4 million as part of a National Institutes of Health initiative called "Big Data to Knowledge" (BD2K). [More]
Discovery offers promising new avenue for prevention, treatment of type 2 diabetes

Discovery offers promising new avenue for prevention, treatment of type 2 diabetes

The surprising discovery of a previously unidentified class of lipid molecules that enhance insulin sensitivity and blood sugar control offers a promising new avenue for the prevention and treatment of type 2 diabetes. [More]
Researchers are developing compounds to combat causative agents of periodontitis

Researchers are developing compounds to combat causative agents of periodontitis

A total 12 million Germans suffer from periodontitis. If the inflammation remains untreated, this could lead to tooth loss. However, it is also suspected of triggering many other diseases, like cardiopulmonary diseases. Researchers are studying the interactions, and developing compounds to combat the causative agents. [More]
NIH announces high-risk, high-reward grants for UCSF researchers

NIH announces high-risk, high-reward grants for UCSF researchers

UC San Francisco researchers received five awards announced this week by the National Institutes of Health (NIH) for high-risk, high-reward scientific research projects. Their work will focus on novel approaches for diagnosing and treating diseases ranging from autoimmune and chronic inflammatory diseases, to cancer, diabetes and neurological disorders. [More]
State highlights: States and drug prices; Ariz. limiting Sovaldi for patients; L.A. boosts uninsured care by $61 million

State highlights: States and drug prices; Ariz. limiting Sovaldi for patients; L.A. boosts uninsured care by $61 million

Because of its high cost, some state Medicaid programs and prison systems are refusing to provide Sovaldi to any but the sickest patients. Most recently, Oregon last month threatened to limit access to the drug unless it can get Sovaldi at a deeply discounted price. But Sovaldi is only the beginning. Expensive new treatments for certain cancers, rheumatoid arthritis and other conditions also have rattled Medicaid officials, patients and health care providers. What can states do to hold down drug costs? Drug pricing is a complicated and opaque process. [More]
UCSF researchers receive five NIH awards for high-risk scientific research projects

UCSF researchers receive five NIH awards for high-risk scientific research projects

UC San Francisco researchers received five awards announced this week by the National Institutes of Health for high-risk, high-reward scientific research projects. Their work will focus on novel approaches for diagnosing and treating diseases ranging from autoimmune and chronic inflammatory diseases, to cancer, diabetes and neurological disorders. [More]
OMRF scientist selected to receive EMD Serono's Grant for Multiple Sclerosis Innovation

OMRF scientist selected to receive EMD Serono's Grant for Multiple Sclerosis Innovation

An Oklahoma Medical Research Foundation scientist has been selected to receive one of only five Grants for Multiple Sclerosis Innovation awarded this year by the pharmaceutical company EMD Serono. [More]
Medac Pharma launches Rasuvo (methotrexate) injection for patients with RA, pJIA and psoriasis

Medac Pharma launches Rasuvo (methotrexate) injection for patients with RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company, has announced the launch of its lead product Rasuvo (methotrexate) injection for patients with rheumatoid arthritis (RA), poly-articular-course juvenile idiopathic arthritis (pJIA) and psoriasis in the U.S. [More]
Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that a Phase 2a proof-of-concept study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did not respond to intranasal corticosteroids. [More]
Early exposure to marijuana can lead to immune-related diseases in adulthood

Early exposure to marijuana can lead to immune-related diseases in adulthood

When it comes to using marijuana, new research, involving mice and published in the October 2014 issue of the Journal of Leukocyte Biology, suggests that just because you can do it, doesn't mean that you should. That's because a team of Italian scientists have found that using marijuana in adolescence may do serious long-term damage to the immune system. [More]
New approach to create treatments for osteoporosis, autoimmune diseases

New approach to create treatments for osteoporosis, autoimmune diseases

Scientists have developed an approach to creating treatments for osteoporosis and autoimmune diseases that may avoid the risk of infection and cancer posed by some current medications. [More]
TSRI scientists awarded DARPA grant to build artificial immune system

TSRI scientists awarded DARPA grant to build artificial immune system

Scientists from both campuses of The Scripps Research Institute have been awarded a total of $7.9 million from the Defense Advanced Research Projects Agency of the U.S. Department of Defense. [More]
NIH awards grants to 11 research groups to establish AMP RA/Lupus Network

NIH awards grants to 11 research groups to establish AMP RA/Lupus Network

The National Institutes of Health has awarded grants to 11 research groups across the United States to establish the Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus (AMP RA/Lupus) Network. [More]
EYLEA Injection gets approval in Japan for treatment of myopic CNV

EYLEA Injection gets approval in Japan for treatment of myopic CNV

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare for EYLEA (aflibercept) Injection for myopic choroidal neovascularization (myopic CNV). [More]
TSRI scientists devise new vancomycin-based antibiotic to rout resistant bacteria

TSRI scientists devise new vancomycin-based antibiotic to rout resistant bacteria

Scientists at The Scripps Research Institute have devised a new antibiotic based on vancomycin that is powerfully effective against vancomycin-resistant strains of MRSA and other disease-causing bacteria. [More]
3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I). [More]
MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

Nektar Therapeutics reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK (naloxegol) tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. [More]